The Second Annual
`IBC International Conference on
`
`December 16-18, 1991 • Omni San Diego Hotel •San Diego, CA
`
`Organized by: •
`
`International Busines..4' Communications
`
`me USA Conference Inc. • 8 Plea ant Street, Bldg. D • South Natick, Mass. 01760
`(508) 650--4700
`
`1 of 6
`
`BI Exhibit 1120
`
`
`IBC International Conference on
`
`December 16-18, 1991 • Omni San Diego Hotel •San Diego, CA
`
`Organized by: •
`
`International Busines..4' Communications
`
`me USA Conference Inc. • 8 Plea ant Street, Bldg. D • South Natick, Mass. 01760
`(508) 650--4700
`
`1 of 6
`
`BI Exhibit 1120
`
`
`
`WELCOME
`
`IBC USA Conferences welcomes you co Antibody Engineering.
`
`No meeting is truly successful if it simply serves the purpose of transferring information. We hope
`in[eractions between lhe speakers and Lhe audience will be1p you gain insights rhac you can use today.
`
`We strongly encourage your participation throughout the conference and have allowed time for you
`~se questions co the speakers. Ample rime for informal interactions has also been allocaced
`oughouc the day. These encounters will complement both the speaker pn:sentations and the written
`·erial.
`
`Our staff members are available throughout the conference to provide assiscance. Please do not
`~tate [Q call on us. We thank you for joining us!
`
`~J!Jl
`
`Phillips Kuhl
`Conference Director
`
`6# ~~-/ 44-/
`Gail Scho
`Conference Manager
`
`Susan Hamano
`Christine Andrews
`Conference Coordinator
`Conference Coordinacor
`!BC USA Conferences
`
`~ Delegates are required to wear their bat$ges at all times. Those without their badges will not be admitted.
`
`2 of 6
`
`BI Exhibit 1120
`
`
`
`ANTIBODY ENGINEERING
`
`Schedule of Events
`
`Welcome & Introduction • Speaker Contacts • Speaker Presentations
`
`Sunday, December 15, 1991
`
`p.m.-10:30 p.m. Early Registration
`
`Monday, December 16, 1991
`
`~. a.m.-8:30 a.m.
`
`Rtgmrauon, Poster St1-up & Cof!u
`
`ENGINEERING TO AVOID HAMA
`CHAIRMAN'S OPENING REMARK
`Dr. Sherif L Morrl\on, Pro/tsS()r of M1crobwlor1 and Molecular Gene1irs, Member of the Moucwlar Bialogy /1U1il11'U, UCLA
`
`8:30
`
`8:35 HUMANIZED Al\TIBODIES FOR THERAPY
`Dr. Cary Qurrn, Vice Preside.111, Resca~h. Proteut Design Lab.f, Inc
`
`9:05
`
`FRAMEWORK CHOICE & RESIDUE SUBSTlTUTION FOR HUMANIZE D
`VENEERED ANTIBODIE
`Dr. G~orae E. Mark ID, D;,1ec1or, Ct'llular &. Mole4ular Bwlofl), Mud SJi/Jrp &. DoivnL RCRarch LaborOJOriu
`
`9:35 USE OP A VACCINIAfli SYSTEM TO RAPIDLY ANALYZE HUMA1'1ZED & OTHER
`ENGINEERED SJNGLE-CHArN FV'S
`Dr. S)·d Johnson, R1.1~h Sc~NISI. Mcdlmnu<nt!, I~
`
`10:05
`
`Rtfrtshment Brtak & Posttrs
`
`10:45
`
`11:15
`
`FUNCTIONAL ANALYSIS OF HlJMA1'1ZED OKTJ & OKT4A
`Dr. Ro~rt A. Zh In, Pn.ocipal Sc~1111n, 810/ech. R W Johl'ISOl'I Phannauiuical R~ic ln.s1uuu
`
`BIOACTIVE PEPTIDE DESIGN BASED ON ANTIBODY HYPERVARIABLE REGION STRUCTURE
`Dr. Will lam V. Wllllams, Di!partmDlJ of Me.dJL~ lru\lus1ry of Pmn.ry/wJnill School of MrdiciN
`
`11:45 ORAL PRESENTATION OF SELECTED POSTERS
`
`12:00
`
`PANEL DISCl:SSION
`
`12:30
`
`Lu.ncheon
`
`EXPRESSION & ENGINEERING
`
`I :~.5 CHA IR~1Al\' REMARK
`Or. James D. M11rks, Rularch Sc~nJtsr. Medical Rt~~arch Cowteil lUK 1
`
`1:50 ANTIBODY E~G~EERING RY E1"ZYMATIC IJ'WERSE PCR
`Dr. Wlllrm P. C. 1emmer. Seruor Rt~larch Srnwi.11. H)brru:cic, /nc
`
`2:20 MAK.11\G Hl"1Al'i A~TIBODIES U ING PHAGE ' £LECTIO.
`Dr. James D. \1urks
`
`3 of 6
`
`BI Exhibit 1120
`
`
`
`2:50
`
`IN VITRO AFFINITY MATURATION BY SITE DIRECTED MUTAGENESIS
`Dr. WUJlam D. Hme, CN.ef Sc10tJiflc Officer. IXSYS. Inc
`
`3:20 Rtfru hmen1 Break & Postt rs
`
`4:00 ANTIBODY ENGINEERING FOR MICROBIAL EXPRESSION & THERAPEUTIC USE
`Dr. A mold H. Hon.tu, Dvt!ctor of Molttwlar Mu:robiology, XOMA Corpora11.0n
`
`4 :30
`
`R ECENT ADVANCES WITH CATALYTIC A.NTIBODIES
`Dr. Mark A.. Gallop, S1ajf Scienlist, B ioorganic CJmmstry, A]hm.tlx Rtsearch /ns1ui.u
`
`5:00 ORAL PRESENTATION OF SELECTED POSTERS
`
`5:15
`
`PANEL DISCUSSION
`
`5:45 Clo.st! of Day Ont
`
`Tuesday, December 17, 1991
`
`7:30 Coffu &: Pos11m.
`
`Bl-SPECIFIC & Bl-FUNCTIONAL
`
`8:00 CHAIRMAN' S RF.MARKS
`Dr. SMrle L. Murraon, Professm of M1uob1olo1fY ll1lil Molt!t:ulcv Gmt1ics. Mtmbtr of'"' Mokcular Biology /11S1itwie. UCLA
`
`8:05 OVERCOMING ANTIDODY BLOCKAGE USING Bl-SPECIFIC ANTIBODIES
`Dr. Satban 8 . Dlnces, \'ice Prtsidefll Mtd.aru. Inc
`
`8'.35
`
`9:05
`
`RF.SF.A RCH & CLJNICAL EXPERIEJ\CE WITH 81-SPEc m c ANTIBODIES
`Dr. Joesph G. Major, Sef'l.IOr Resrwch Sc11n11s:, H}bmcch, /ncorporaud
`
`TARGETING C YTOTOXJCIT\' WITH A Bl-SPECIFIC ANTIBODY DIRECTED TO
`C-ERB-2 & HUMAN FC"y RECEPTOR Ill
`Dr. Dnld 8 . Ring, SMWr Sc1cnJut. Dvecior. Dt:JX1rlme1t1 of lmnumoloi). Ct!1w.t CorportJJ1on
`
`9 35 Refrtshmem BreaJ. & Pos1ers
`
`10:15
`
`PRODUCTION OF A SINGLE-CHAIN Bl·SPECIF1C ANTIBODY
`Dr. Andttw J. T. Gfl>rgr , £xpu~n1al lmnuuiolou Branrh, /\aJwnal Can£U /n.rriwu , Na1iona/ lnstilwu.s of H t:ahh
`
`10:45 GENETIC ENGINEERING Of ASTIBODIES FOR NOVEL FUNCTIONS
`Dr. herle L. ~ o rris.on
`
`11 : 15 ORAL PRESENTATION Of SELECTED POSTERS
`
`l 1:30
`
`PANEL DL'iCL'SSION
`
`12:00
`
`lunch Br~alr.
`
`HUMAN MONOCLONALS
`
`1:15
`
`C HAIRMA1'' S RF.MARKS
`Dr. \1urk C. Ght.~} . Edi1or 111 -Clut:/, Humlll1Afllibodi~s aNJ llybridomaJ and Prt:sidm. Sc1-CloM, Jnc.
`
`1:20 HUMA"li MONOCLONAL IMAGJ'iEERJl\G
`Dr. !\tan. C. Gia&)
`
`1:50 HUMA1' A'ITJBODIES B\' RF:PERTOIRE L'LO!' l:"JG
`Dr. Carl05 F. B .. rb~, .>\.uu1an1 Prvfe.rn., Scripr" Re\tJn h Jnswu.u
`
`4 of 6
`
`BI Exhibit 1120
`
`
`
`2:20
`
`PRODUCTION &c APPLICATION OF HUMAN MONOCLONAL ANTIBODIES
`Dr. S. M. Jwasa, Ru~ardt MDNJ10. Bwlog)' Res~n l.AboratonCJ, TaiwJJJ ClwluC41 /ndlUlria, LJd.
`
`2:50 Refreshment Break & Postus
`
`3:30
`
`IN VITRO IMMUNIZATION METHODS FOR PRODUCTION OF HUMAN IGG
`MONOCLONAL ANTIBODIES
`Dr. Paula Boerner, Dirttl"' of Celi Baolog:-. IXSYS. Inc
`
`4:00 DEVELOPMENT OF A HUMAN lrt1MllNOGLOBULIN TRANSGENIC MOUSE
`Dr. Slls Loabrr&, SotJDT Scu:fllUt. Genl'lw.rm buul'IQliQNJJ
`
`4:30 ORAL PRESENTATION OF SELECTED POSTERS
`
`4:45
`
`PANEL DISCUSSION
`
`5: 15
`
`POSTERS
`
`6:00 Cocklail Rtception
`
`7:30 Close of Day T"'"'
`
`'tVednesday, Decernber1B. 1991
`
`7:30 Coffu & Posrtrs
`
`CLINICAL EXPERIENCE
`
`8:00 CHAIRMAN'S REMARKS
`Dr. Albfrt F. LoBugflo, D1ncror Compr~MllJm Cancer Cefllu, Professor of MemciM, Univvsll) of Alabama a18inn111gltam
`
`8:05
`
`8:35
`
`PHARMACOKINETICS & 11.fMUNE RESPO~SE OF MURINE & CHIMERIC ANTIBODIES
`Dr. AJbtrt F. LoBugJlo
`
`CLINICAL EXPERIENCE WITH THE L6 A"ffl·CARCINO\!A ANTIBODY
`Dr. Dalt' E. Yt!lton, SciLNISI, Brmol-M)u.r Sq1,.bb Pharm.xewicat Research l1U11lllll
`
`9:05 CLINICAL RESULTS WITH CHIMERIC & HUMAN MONOCLONAL ANTIBODIES
`Dr. Jamti N. Wood~, Suu01T \-'iu PresuitnJ, C miocor. ll'IC
`
`9:35 Refreshment Bnak and Poscers
`
`10:15
`
`10:45
`
`PATIE1'T RESPONSE TO CHIMERIC 872.3
`l>r. Ttrt) S. Bakrr, Pr111C1pat Sc~111is1. Crlltuh, ud
`
`IJliTERNAL IMAGE ANTIGEJ'liS AS THERAPEUTIC MODA.LITTF.S FOR CANCER &
`INFECTIOUS DISEASES
`Dr. Samurl D. Waksal, P~s1dU1J and CEO. JmCJ.oM 51.rtmu Inc
`
`11:J5 ORAL PRESENTATION OF ELECTED POSTER
`
`11 :30
`
`PA!liEL DI Cl: 'SIOJ'li
`
`12:00
`
`Clos~ of Conftr~nu
`
`5 of 6
`
`BI Exhibit 1120
`
`
`
`CHOOSING THE BEST FRAMEWORK TO USE IN THE 'HUMANIZATION'
`OF AN ANTIBODY BY CCR-GRAFTING : SUGGESTIONS FROM 3-0
`STRUCTURAL DATA
`
`Eduardo A. Padlan
`Laboratory of Molecular Biology, National Institute of Diabetes and
`Digestive and Kidney Diseases, National Institutes of Health, Bethesda,
`Maryland 20892, U.S.A.
`
`SUMMARY
`
`In order to ensure the preservation of antigen-binding properties.
`when an antibody is 'humanized' by CDR-grafting, all the framework
`residues, that could influence the structure of its combin ing site, must be
`retained. Examination of the structures of various Fabs reveals that those
`residues are different for different antibodies, emphas1Z1ng the need for a
`we ll-characterized, three-d1mens1onal structure to serve as a guide
`during 'humanization'. A hypothetical 'humanization' by CDR-grafting of
`the mudne antibody, J539, that attempts to preserve the ligand-binding
`prupe:1·ties of th e molecule:, aer.1onstrates that hurnan 1mmunoglobulrn
`sequences are available that. w1 h only a few mu ations, could serve as
`the best framework for the 'humanization' of this antibody.
`
`6 of 6
`
`BI Exhibit 1120
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
